Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael B. Dilling"'
Autor:
Leonid Metelitsa, Ross Durland, Michael B. Dilling, Anne C. DiSante, Christine E. Flynn, Venkat Selvamanickam
Publikováno v:
Technology & Innovation. 21:169-177
Collaborations between academia and industry are growing in scope, duration, and sophistication. The best collaborations recognize the unique strengths and skill sets of both parties and are structured to leverage what each party does best. In many c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1ba24f0b5cdc92b5c271556b227c72e
https://doi.org/10.21300/21.2.2020.169
https://doi.org/10.21300/21.2.2020.169
Autor:
Corrie E.M. Gidding, Glen S. Germain, Michael B. Dilling, Tiny G. J. Meeuwsen-de Boer, Richard A. Ashmun, Siebold S. N. de Graaf, Karen A. Veverka, Willem A. Kamps, Peter J. Houghton
Publikováno v:
Cancer Chemotherapy and Pharmacology, 45, 1, pp. 21-30
Cancer Chemotherapy and Pharmacology, 45, 21-30
Cancer Chemotherapy and Pharmacology, 45, 21-30
Purpose: Recombinant human insulin-like growth factor I (rhIGF-I) has been reported to ameliorate vincristine-induced neuropathy, the dose-limiting side effect of this antimitotic anticancer drug. However, rhIGF-I also might have adverse effects, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9e9bd44d3ea68796cf676d5108bba51
https://hdl.handle.net/2066/184670
https://hdl.handle.net/2066/184670
Autor:
Hajime Hosoi, Takuma Shikata, Robert T. Abraham, Mary K. Danks, Michael B. Dilling, John C. Lawrence, Aleksander Sekulic, Linda N. Liu, Peter J. Houghton
Publikováno v:
Molecular Pharmacology. 54:815-824
Rapamycin is a potent cytostatic agent that arrests cells in the G1 phase of the cell cycle. The relationships between cellular sensitivity to rapamycin, drug accumulation, expression of mammalian target of rapamycin (mTOR), and inhibition of growth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efb39c8d22714f353c092017a28ea32
https://doi.org/10.1124/mol.54.5.815
https://doi.org/10.1124/mol.54.5.815
Autor:
Franklin C. Harwood, Peter J. Houghton, Lili Shu, Michael B. Dilling, Shile Huang, Hidenori Ichijo, John Easton
Publikováno v:
Molecular cell. 11(6)
Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces apoptosis of cells lacking functional p53. Cells expressing wild-type p53 or p21(Cip1)arrest in G1 and remain viable. In cells lacking functional p5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7bf4d365463b2e3cd145db0a6d4dff0
https://pubmed.ncbi.nlm.nih.gov/12820963
https://pubmed.ncbi.nlm.nih.gov/12820963
Autor:
Peter J. Houghton, Xiongwen Zhang, Michael B. Dilling, Glen S. Germain, Franklin C. Harwood, Lorina Dudkin, Arun L. Jayaraman
Publikováno v:
The Journal of biological chemistry. 277(16)
To determine whether inhibition of either the ribosomal p70 S6 kinase or eukaryotic initiation factor (eIF) 4E pathways downstream of the mammalian target of rapamycin, mTOR, contributes to rapamycin-induced growth arrest, clones of Rh30 rhabdomyosar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5c95348ab4df5deb69f74e6f61afb1a
https://pubmed.ncbi.nlm.nih.gov/11847216
https://pubmed.ncbi.nlm.nih.gov/11847216